Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

Eisai and Biogen have officially launched Leqembi (lecanemab) in South Korea, marking a significant step in Alzheimer’s ...

BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud that CareMed, a ...

STOCKHOLM, Nov. 28, 2024 /PRNewswire/ - BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced today that Leqembi ® (generic name: lecanemab) has been launched in South Korea.

BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced today that Leqembi® (generic name: lecanemab) has been launched in South Korea. Leqembi received approval in South Korea ...

BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced today that Leqembi® (generic name: lecanemab) has been launched in South ...

Lecanemab, marketed as Leqembi, is the first drug targeting the root cause of Alzheimer’s disease to be approved by the ...

Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has ...

There are a handful of common medicines that, according to doctors, if taken for a long time, can spike your risk of dementia ...

Japanese drugmaker Eisai today that the humanized antisoluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) has been launched in South Korea.